NasdaqGS:IDYABiotechs
Is IDEAYA Biosciences (IDYA) Quietly Assembling a Focused MTAP-Deletion Oncology Franchise?
IDEAYA Biosciences recently enrolled the first patient in its Phase 1 trial of IDE892 for MTAP-deleted solid tumors and outlined a refocused precision oncology pipeline, including combinations with its MAT2A inhibitor IDE397 and deprioritization of Trodelvy-related studies.
A key insight is IDEAYA’s effort to build a coherent MTAP-deletion and CDKN2A-deficiency franchise, aiming to address genetically defined patient groups that currently lack targeted treatment options.
Against this...